Close Menu

NEW YORK (GenomeWeb) – Illumina and Sequenom said today that they will pool all their owned and in-licensed intellectual property relating to their respective noninvasive prenatal tests, including those that are the subject of interference proceedings, effectively ending four years of patent disputes.

Under the agreement, Illumina will have exclusive worldwide rights to use the pooled IP to develop and sell in vitro diagnostic kits for NIPT and to license the IP to third-party laboratories that want to develop and sell their own laboratory-developed tests.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.